Trial Profile
A 5-year post-marketing safety study for dalfampridine extended release tablets in multiple sclerosis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Oct 2015
Price :
$35
*
At a glance
- Drugs Fampridine (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- 27 Oct 2015 New trial record
- 22 Oct 2015 According to an Acorda media release, 5-year post-marketing safety data from this trial was presented at the 31st Congress of the European Committee for the Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting.
- 07 Oct 2015 According to an Acorda media release, 5-year post-marketing safety data from this trial will be presented at the 31st Congress of the European Committee for the Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting.